Capricor Therapeutics Target of Unusually Large Options Trading (NASDAQ:CAPR)

Capricor Therapeutics Inc (NASDAQ:CAPR - Get Free Report) was the recipient of unusually large options trading on Monday. Stock investors bought 4,400 call options on the company. This is an increase of 37% compared to the typical volume of 3,206 call options.

Analysts Set New Price Targets

CAPR has been the subject of a number of recent research reports. HC Wainwright reissued a "buy" rating and set a $77.00 price objective on shares of Capricor Therapeutics in a report on Tuesday. Cantor Fitzgerald boosted their price objective on Capricor Therapeutics from $25.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $34.50.

Capricor Therapeutics Price Performance

Shares of NASDAQ CAPR traded down $1.05 during midday trading on Wednesday, reaching $12.65. The company's stock had a trading volume of 2,295,020 shares, compared to its average volume of 1,337,492. Capricor Therapeutics has a 12-month low of $3.52 and a 12-month high of $23.40. The firm has a 50 day moving average price of $14.40 and a 200-day moving average price of $13.93. The stock has a market capitalization of $575.20 million, a P/E ratio of -11.93 and a beta of 4.08.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Capricor Therapeutics by 44.4% in the fourth quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company's stock worth $31,420,000 after acquiring an additional 700,243 shares during the period. Farallon Capital Management LLC bought a new position in shares of Capricor Therapeutics in the fourth quarter worth $31,056,000. Geode Capital Management LLC boosted its holdings in shares of Capricor Therapeutics by 37.8% in the fourth quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company's stock worth $12,139,000 after acquiring an additional 241,279 shares during the period. Altium Capital Management LLC boosted its holdings in shares of Capricor Therapeutics by 150.5% in the fourth quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company's stock worth $9,853,000 after acquiring an additional 429,000 shares during the period. Finally, Woodline Partners LP bought a new position in shares of Capricor Therapeutics in the fourth quarter worth $8,693,000. Hedge funds and other institutional investors own 21.68% of the company's stock.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc NASDAQ: CAPR is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.